NCT01666119View on ClinicalTrials.gov

An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Opioid Dependence
Interventions
DRUG

BEMA Buprenorphine NX films

BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.

Trial Locations (10)

21201

Baltimore

32256

Jacksonville

32751

Maitland

33161

North Miami

35215

Birmingham

35565

Haleyville

66206

Prairie Village

84106

Salt Lake City

02720

Fall River

07823

Belvidere

Sponsors
All Listed Sponsors
lead

BioDelivery Sciences International

INDUSTRY

NCT01666119 - An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects | Biotech Hunter | Biotech Hunter